Zanubrutinib and G-CHOP for untreated follicular lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of targeted therapy (zanubrutinib) with standard chemotherapy (G-CHOP) for people with untreated follicular lymphoma that is intermediate or high risk. The goal is to see if this combination can improve outcomes compared to standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of follicular lymphoma (grades 1, 2, or 3a).
- You have not received any prior treatment for lymphoma.
- Your lymphoma needs treatment based on specific criteria (called GELF criteria).
- You are between 18 and 75 years old.
- You have stage II, III, or IV lymphoma.
- Your lymphoma is considered intermediate or high risk based on a scoring tool (FLIPI).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted therapy (zanubrutinib) and chemotherapy (G-CVP) for people with follicular lymphoma who have not had treatment before. It aims to see if this combination is safe and effective.
This trial tests a 3-drug combination (Zanubrutinib, Bendamustine, and Obinutuzumab) for people with advanced follicular lymphoma who have not had treatment before. The goal is to see if a fixed-duration treatment plan can improve outcomes.
This trial tests a combination of targeted therapy (zanubrutinib) and chemotherapy (GCVP) for people with follicular lymphoma who have not had treatment before. The goal is to see if this combination is effective and safe.
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) as a first treatment for follicular lymphoma. The goal is to see if this triple therapy works safely and effectively.
This trial tests a combination of two targeted drugs, zanubrutinib and obinutuzumab, for people who have just been diagnosed with follicular lymphoma. The goal is to see if this combination works well and is safe.
This study is testing a combination of three drugs—zanubrutinib, obinutuzumab, and lenalidomide—as a first treatment for people with a certain type of follicular lymphoma that is considered high-risk. The goal is to see if this combination is safe and effective in controlling the cancer.
Hear when a new FL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.